01—Abstract
Summary
Summary of the 8-K filed June 18, 2025. Cited figures are marked; the original filing is the authoritative source.
Revolution Medicines, Inc. (RVMD) filed a Form 8-K on June 18, 2025 under Item 5.02 (Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers) to disclose a board change.
Barbara Weber, M.D., communicated her decision to resign from the Company's Board of Directors, including her roles as a director, member of the Nominating and Corporate Governance Committee, and member of the Research & Development Committee. The resignation is effective immediately prior to the Company's 2025 annual meeting of stockholders, scheduled for 7:30 a.m. PT on June 26, 2025.
The filing states that Dr. Weber's resignation is connected to the activation of the clinical study under the ongoing collaboration between the Company and Tango Therapeutics, Inc. The filing explicitly states that the resignation was not the result of any disagreement with the Company or any matter relating to the Company's operations, policies or practices. For investors, this is a governance update rather than a financial disclosure.
The filing contains no financial results, financial figures, or guidance. Its most notable element is the link between the director's departure and an active clinical study under the existing Tango Therapeutics collaboration.
02—Key points
Key Highlights
- Barbara Weber, M.D. communicated her resignation from the Board of Directors on June 18, 2025.
- Dr. Weber also steps down from the Nominating and Corporate Governance Committee and the Research & Development Committee.
- The resignation takes effect immediately prior to the 2025 annual meeting of stockholders, scheduled for 7:30 a.m. PT on June 26, 2025.
- The filing links the resignation to the activation of the clinical study under the ongoing collaboration with Tango Therapeutics, Inc.
- The filing states the resignation was not due to any disagreement with the Company or any matter relating to its operations, policies or practices.
- The filing contains no financial results or financial figures.
03—Questions
Frequently Asked Questions
Who is leaving the Revolution Medicines board?
Barbara Weber, M.D., is resigning from the Board of Directors, along with her roles on the Nominating and Corporate Governance Committee and the Research & Development Committee.
When does the resignation take effect?
The resignation is effective immediately prior to the Company's 2025 annual meeting of stockholders, scheduled for 7:30 a.m. PT on June 26, 2025.
Why is Dr. Weber resigning?
The filing says the resignation is in connection with the activation of the clinical study under the ongoing collaboration between the Company and Tango Therapeutics, Inc. It also states the resignation was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices.
Does this filing disclose any financial results or guidance?
No. This 8-K covers only a board departure under Item 5.02 and does not include financial results, figures, or guidance.
04—Continue